Eun Ju Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eun Ju Song has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ah-Hyeon Jo
Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 46231, Republic of Korea
1 shared publication - Bae-Hoon Kim
Institute of Rare Genetic Disease, PRG S&Tech Co., Ltd., Busan 46274, Republic of Korea
1 shared publication - Bum-Joon Park
Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Korea.
1 shared publication - Cailin E. Kellum
Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham (C.E.K., J.S.P.).
1 shared publication Cesar A. Romero
Division of Nephrology, Department of Medicine (C.A.R.), Emory University, Atlanta, GA
1 shared publicationChristian Park
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (M.D.C., Y.K., D.W.K., K.I.B., E.J.S., J.A.B.-K., C.P., R.-C.H., L.C., V.K., H.J.).
1 shared publication
Latest Publications
- 1 December 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (12) , 2292-2295
Flow-Sensitive HEG1 Controls eNOS Activity to Prevent Endothelial Dysfunction, Hypertension, and Atherosclerosis
- 1 December 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (12) , 2292-2295
Flow-Sensitive HEG1 Controls eNOS Activity to Prevent Endothelial Dysfunction, Hypertension, and Atherosclerosis
- Open Access
Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson–Gilford Progeria Syndrome
Hutchinson–Gilford Progeria Syndrome (HGPS) is an ultra-rare human premature aging disorder that precipitates death because of cardiac disease. Almost all cases of HGPS are caused by aberrant splicing of the LMNA gene that results in the production of a mutant Lamin A protein termed progerin. In our previous study, treatment with Progerinin has been shown to reduce progerin expression and improve aging phenotypes in vitro and in vivo HGPS models. In this record, cardiac parameters (stroke volume (SV), ejection fraction (EF), fractional shortening (FS), etc.) were acquired in LmnaWT/WT and LmnaG609G/WT mice fed with either a vehicle diet or a Progerinin diet by echocardiography (from 38 weeks to 50 weeks at various ages), and then the cardiac function was analyzed. We also acquired the tissue samples and blood serum of LmnaWT/WT and LmnaG609G/WT mice for pathological analysis at the end of echocardiography. From these data, we suggest that the administration of Progerinin in the HGPS model mouse can restore cardiac function and correct arterial abnormalities. These observations provide encouraging evidence for the efficacy of Progerinin for cardiac dysfunction in HGPS.
Open AccessProgerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson–Gilford Progeria Syndrome
Hutchinson–Gilford Progeria Syndrome (HGPS) is an ultra-rare human premature aging disorder that precipitates death because of cardiac disease. Almost all cases of HGPS are caused by aberrant splicing of the LMNA gene that results in the production of a mutant Lamin A protein termed progerin. In our previous study, treatment with Progerinin has been shown to reduce progerin expression and improve aging phenotypes in vitro and in vivo HGPS models. In this record, cardiac parameters (stroke volume (SV), ejection fraction (EF), fractional shortening (FS), etc.) were acquired in LmnaWT/WT and LmnaG609G/WT mice fed with either a vehicle diet or a Progerinin diet by echocardiography (from 38 weeks to 50 weeks at various ages), and then the cardiac function was analyzed. We also acquired the tissue samples and blood serum of LmnaWT/WT and LmnaG609G/WT mice for pathological analysis at the end of echocardiography. From these data, we suggest that the administration of Progerinin in the HGPS model mouse can restore cardiac function and correct arterial abnormalities. These observations provide encouraging evidence for the efficacy of Progerinin for cardiac dysfunction in HGPS.